Hincus Pharmaceuticals Pharmaceutical Import Profile — Russia (DGFT 2022–2026)

Name: Hincus Pharmaceuticals Pharmaceutical Import Records from India — 3 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hincus Pharmaceuticals — Pharmaceutical Importer Profile (2026) | 3 Products, $1.3M Trade | TransData Nexus

Hincus Pharmaceuticals

Pharmaceutical Importer · Russia · Antimalarial & Antiparasitic Focus · $1.3M Total Trade · DGFT Verified

Hincus Pharmaceuticals is a pharmaceutical importer based in Russia with a total trade value of $1.3M across 3 products in 2 therapeutic categories. Based on 39 verified import shipments from Indian Customs (DGFT) records, Hincus Pharmaceuticals is the #1 buyer in 1 product including Pyrantel. Hincus Pharmaceuticals sources from 1 verified Indian supplier, with Ipca Laboratories Limited accounting for 100.0% of imports.

Hincus Pharmaceuticals — Import Portfolio & Supplier Network

Hincus Pharmaceuticals import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hincus Pharmaceuticals?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ipca Laboratories Limited	$11.5M	314	100.0%

Hincus Pharmaceuticals sources from 1 verified Indian supplier across 224 distinct formulations. The sourcing is highly concentrated — Ipca Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Hincus Pharmaceuticals Import?

Formulation	Value	Ships
Harmless medicines: normax eye/ear drops5ml (norfloxacin) [1x5ml per	$248.7K	6
Harmless medicines:tenoric 100MG	$200.0K	4
Harmless medicines: nemozole-400MG	$150.0K	3
Harmless medicines: tenoric 50MG	$150.0K	3
Harmless medicines: nemozole 100MG/5ML	$150.0K	3
Harmless medicines nemozole-400MG tablets (1x1s) (279720 x1x1s Pack) unit rateusd 1.4400 per	$150.0K	3
Harmless medicines nemozole-400MG tablets (1x1s) (312000x1x1s Pack) unit rateusd 1.4400 per	$150.0K	3
Harmless medicines nemozole-400MG tablets (1x5s) (116460x1x5s Pack) unit rateusd 6.1500 per	$150.0K	3
Harmless medicines nemozole-400MG tablets (1x5s) (118620x1x5s Pack) unit rateusd 6.1500 per	$150.0K	3
Harmless medicines: lomflox tablets 400MG tablets(lomefloxacin hcl)(1x5s	$150.0K	3
Harmless medicines normax eye / ear drops (1x5ml) (280740 x1x5ml Pack) unit rate usd 1.2100 per 1x5ml	$150.0K	3
Nemozole-400MG tablets(117640x1x5's Pack=588200 tablets)	$150.0K	3
Harmless medicines:tenoric 50MG tablets(125080x2x14's Pack=3502240 tablets)	$141.0K	3
Nemozole-400MG tablets(104580x1x1's Pack=104580 tablets)	$137.0K	3
Harmless medicines:tenoric tablets 100MG	$100.0K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pyrantel	Antimalarial & Antiparasitic	$595.4K	24	18.2%	1
2	Norfloxacin	Advanced Antibiotics	$385.4K	9	3.6%	3
3	Albendazole	Antimalarial & Antiparasitic	$300.0K	6	0.4%	2

Hincus Pharmaceuticals imports 3 pharmaceutical products across 2 categories into Russia totaling $1.3M. The company is the #1 buyer for 1 product: Pyrantel.

Hincus Pharmaceuticals — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hincus Pharmaceuticals is a prominent pharmaceutical importer and distributor based in Russia, specializing in the procurement and distribution of finished pharmaceutical formulations. The company operates as a primary wholesaler, sourcing a diverse range of pharmaceutical products from international suppliers to meet the needs of the Russian healthcare market. Headquartered in Podolsk, Moscow Region, Russia, Hincus Pharmaceuticals plays a pivotal role in ensuring the availability of essential medications across the country.

The company's extensive import activities underscore its significant presence in the Russian pharmaceutical distribution network. By facilitating the entry of a wide array of pharmaceutical products into the Russian market, Hincus Pharmaceuticals contributes to the diversification and enrichment of the domestic pharmaceutical landscape. This strategic positioning enables the company to cater to various therapeutic needs, thereby enhancing the overall healthcare provision within Russia.

2Distribution Network

Hincus Pharmaceuticals maintains a robust distribution network with a central warehouse located in Podolsk, Moscow Region. This strategic location facilitates efficient logistics and timely delivery of pharmaceutical products throughout Russia. The company's logistics capabilities are designed to ensure the swift and secure transportation of medications, adhering to the stringent requirements of the pharmaceutical industry. While specific details regarding additional warehouse locations and geographic coverage beyond Russia are not publicly disclosed, Hincus Pharmaceuticals' established infrastructure indicates a capacity to serve a wide range of regions within the country.

3Industry Role

In Russia's pharmaceutical supply chain, Hincus Pharmaceuticals functions primarily as a wholesaler, importing finished pharmaceutical formulations from international suppliers and distributing them to various stakeholders within the healthcare sector. The company's role is crucial in bridging the gap between global pharmaceutical manufacturers and the Russian market, ensuring the availability of a diverse range of medications to meet the country's healthcare needs. By sourcing products from reputable international suppliers, Hincus Pharmaceuticals contributes to the enhancement of the quality and variety of pharmaceutical products accessible to Russian consumers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hincus Pharmaceuticals

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hincus Pharmaceuticals exhibits a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, IPCA Laboratories Limited. This concentrated sourcing strategy indicates a strong and potentially strategic partnership between Hincus Pharmaceuticals and IPCA Laboratories Limited. The substantial volume of imports from this supplier suggests a reliable and consistent supply chain, which is advantageous for maintaining product availability and meeting market demand.

However, the reliance on a single supplier also presents potential risks, such as supply chain disruptions due to unforeseen events affecting the supplier's operations. To mitigate these risks, it would be prudent for Hincus Pharmaceuticals to consider diversifying its supplier base. Engaging with additional reputable suppliers could enhance supply chain resilience and provide alternative options in case of disruptions. This strategic diversification would contribute to the stability and continuity of Hincus Pharmaceuticals' operations, ensuring a steady supply of pharmaceutical products to the Russian market.

2Supply Chain Resilience

The resilience of Hincus Pharmaceuticals' supply chain is closely tied to its sourcing strategy, particularly the heavy reliance on IPCA Laboratories Limited. While this partnership offers the benefits of a consistent and reliable supply, it also exposes the company to potential vulnerabilities associated with single-source dependency. To bolster supply chain resilience, Hincus Pharmaceuticals could explore establishing relationships with additional suppliers, thereby reducing the impact of potential disruptions from any single source.

Importing Pharmaceuticals into Russia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Russia

1Regulatory Authority & Framework

The primary regulatory authority overseeing the circulation of medicines in Russia is the Federal Service for Surveillance in Healthcare (Roszdravnadzor). This agency is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products within the Russian Federation. The legal framework governing pharmaceutical imports is primarily established by Federal Law No. 61-FZ "On the Circulation of Medicines," enacted on April 12, 2010. This law outlines the procedures for the importation, registration, and distribution of medicinal products in Russia. According to Article 47 of this law, the import of medicines into the Russian Federation must comply with the customs legislation of the Customs Union and Russian Federation legislation.

The marketing authorization pathway for Indian generics involves several key steps:

1. Product Registration: Medicines intended for import must be registered with Roszdravnadzor. This process includes submitting comprehensive documentation, such as clinical trial data, manufacturing details, and quality control information.

2. Import Licensing: Once registered, an import license must be obtained from the Ministry of Industry and Trade of the Russian Federation. This license authorizes the importation of specific medicinal products into Russia.

3. Compliance with Standards: Imported medicines must adhere to Russian pharmacopoeial standards or, in their absence, to normative documentation. A certificate from the manufacturer attesting to compliance with these standards is required.

Import Licensing & GMP

Hincus Pharmaceuticals — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hincus Pharmaceuticals focuses on importing antimalarial and antiparasitic medications, as well as advanced antibiotics. The substantial import value of Pyrantel, Norfloxacin, and Albendazole indicates a strategic emphasis on these therapeutic areas. The market demand for these products is driven by the prevalence of parasitic infections and antibiotic-resistant bacteria in Russia, necessitating a steady supply of effective treatments.

2Sourcing Profile

Hincus Pharmaceuticals' sourcing strategy is heavily concentrated on finished pharmaceutical formulations, primarily from IPCA Laboratories Limited. This focus on finished products allows the company to streamline its operations and ensure the availability of ready-to-use medications in the Russian market. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred sourcing destination for Hincus Pharmaceuticals.

3Market Positioning

Based on its product mix, Hincus Pharmaceuticals serves the wholesale distribution segment of the Russian market. By importing and distributing a range of pharmaceutical products, the company plays a crucial role in supplying medications to various healthcare providers, including hospitals, clinics, and pharmacies. This positioning enables Hincus Pharmaceuticals to influence the availability and accessibility of

Frequently Asked Questions — Hincus Pharmaceuticals

What products does Hincus Pharmaceuticals import from India?

Hincus Pharmaceuticals imports 3 pharmaceutical products across 2 categories. Top imports: Pyrantel ($595.4K), Norfloxacin ($385.4K), Albendazole ($300.0K).

Who supplies pharmaceuticals to Hincus Pharmaceuticals from India?

Hincus Pharmaceuticals sources from 1 verified Indian suppliers. The primary supplier is Ipca Laboratories Limited (100.0% of imports, $11.5M).

What is Hincus Pharmaceuticals's total pharmaceutical import value?

Hincus Pharmaceuticals's total pharmaceutical import value from India is $1.3M, based on 39 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hincus Pharmaceuticals focus on?

Hincus Pharmaceuticals imports across 2 categories. The largest: Antimalarial & Antiparasitic (69.9%), Advanced Antibiotics (30.1%).

Get Full Hincus Pharmaceuticals Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.